Dr. Cynthia L. Verst is President of Real-World & Late Phase Research at Quintiles, a position she was appointed to in 2014.
Dr. Verst has more than 20 years of biopharma experience and a proven track record of late phase operational leadership and innovation. Prior to joining Quintiles, she was Senior Vice President, Global Late Phase Research, for OptumInsight (a division of UnitedHealth Group), where she and her team successfully established a new global Late Phase Research Business Unit. Previously, Dr. Verst and her team established and led Kendle’s global Late Phase Business Unit. She began her career in biopharma at Procter & Gamble Pharmaceuticals as Section Head in its North American Medical and Technical Affairs group, successfully leading the Phase IIIB/IV research requirements of marketed products. Dr. Verst has been directly involved and/or provided executive level oversight to hundreds of Phase IIIB, IV, registries, comparative effectiveness, and Health Economic & Outcomes Research (HEOR) programs, entailing millions of patients and more than 150,000 investigators in over 100 countries.
Dr. Verst was named one of the top women in biotech in 2014 by FierceBiotech, an annual award that spotlights an elite list of 15 women leaders in the life sciences, academia and regulatory roles.
A native of Kentucky, Dr. Verst holds a Pharm.D. and bachelor of science degree in Pharmacy from the University of Cincinnati, a master of science in Structural and Cellular Biology from the University of Illinois, and a bachelor of science degree in Biology and Chemistry from Northern Kentucky University.